Registry for patients with acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry collects data from adult patients who have been newly diagnosed or have relapsed/refractory acute myeloid leukemia (AML). The study aims to gather epidemiological information, evaluate clinical outcomes such as relapse-free survival and overall survival, and document treatment strategies across multiple sites in Germany. By comparing the collected data with population-related tumor registries, the study seeks to enhance understanding of AML demographics and treatment effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* AML according to the WHO (World Health Organization) diagnostic criteria, including acute promyelocytic leukemia
* Age ≥ 18 years. There is no upper age limit.
* Signed written informed consent

Exclusion Criteria:

* there are no exclusion criteria

Where it's running

• Klinikum Mittelbaden
  Baden-Baden, Baden-Wurttemberg, Germany Recruiting
• Universtitätsklinikum Heidelberg
  Heidelberg, Baden-Wurttemberg, Germany Recruiting
• Klinikum Mannheim GmbH
  Mannheim, Baden-Wurttemberg, Germany Recruiting
• Diakonie-Klinikum
  Schwäbisch Hall, Baden-Wurttemberg, Germany Recruiting
• Kliniken Sindelfingen-Böblingen gGmbH
  Sindelfingen, Baden-Wurttemberg, Germany Recruiting
• Robert-Bosch-Krankenhaus GmbH
  Stuttgart, Baden-Wurttemberg, Germany Recruiting

+10 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Christoph Röllig, Prof. Dr.
• Email: christoph.roellig@uniklinikum-dresden.de

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PBSS1113 with azacitidine for AML and higher-risk MDS

  This study tests PBSS1113 together with azacitidine to see if it is safe and may help people with AML or higher-risk MDS who are newly diagnosed and not fit for intense chemotherapy or who have relapsed/refractory disease.

  Recruiting Phase 1/2 Chaser Therapeutics, Inc. · Hangzhou, Zhejiang · NCT07761533

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• Venetoclax TDM in newly diagnosed AML: exposure and prognosis

  This study checks if measuring venetoclax levels and adjusting treatment helps people with newly diagnosed AML who are getting VEN-AZA.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou · NCT07670130

• CAR-T cells targeting CD33 and CLL1 for relapsed or refractory AML

  A one-arm early-stage trial tests whether a patient’s own engineered CAR-T cells (ICG415) can be safely given after conditioning chemotherapy to see if they can help adults with relapsed or refractory AML.

  Recruiting at 2 sites Phase 1 iCell Gene Therapeutics · Nanchang, Jiangxi and 1 other locations · NCT07668557

• Ziftomenib for relapsed/refractory NPM1-mutated AML in Japanese adults

  This study will test whether ziftomenib can help adults with relapsed or refractory NPM1-mutated AML who have few other options.

  Recruiting at 15 sites Phase 2 Kyowa Kirin Co., Ltd. · Chiba and 19 other locations · NCT07623616

• VABu Conditioning for elderly AML patients undergoing stem cell transplant

  This trial tests a VABu conditioning regimen to see if it helps older AML patients before allogeneic stem cell transplantation.

  Recruiting Phase 2/3 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07583888

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.